 Connection
Gregory Forlenza to United States
This is a "connection" page, showing publications Gregory Forlenza has written about United States.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.410 |
|
|
|
-
Levy CJ, Carlow D, Swift D, Rittgers-Simonds R, Gronroos NN, Walker V, Buysman EK, Forlenza G. Real-World HbA1c Following Initiation of the Omnipod 5 Automated Insulin Delivery System. Diabetes Technol Ther. 2026 May; 28(5):483-489.
Score: 0.067
-
Forlenza GP, DeSalvo DJ, Aleppo G, Wilmot EG, Berget C, Huyett LM, Hadjiyianni I, Méndez JJ, Conroy LR, Ly TT, Sherr JL. Real-World Evidence of Omnipod® 5 Automated Insulin Delivery System Use in 69,902 People with Type 1 Diabetes. Diabetes Technol Ther. 2024 08; 26(8):514-525.
Score: 0.059
-
Forlenza GP, Carlson AL, Galindo RJ, Kruger DF, Levy CJ, McGill JB, Umpierrez G, Aleppo G. Real-World Evidence Supporting Tandem Control-IQ Hybrid Closed-Loop Success in the Medicare and Medicaid Type 1 and Type 2 Diabetes Populations. Diabetes Technol Ther. 2022 11; 24(11):814-823.
Score: 0.053
-
Forlenza GP. Insulin Infusion Sets and Continuous Glucose Monitoring Sensors: Where the Artificial Pancreas Meets the Patient. Diabetes Technol Ther. 2017 04; 19(4):206-208.
Score: 0.037
-
Forlenza GP, Pyle LL, Maahs DM, Dunn TC. Ambulatory glucose profile analysis of the juvenile diabetes research foundation continuous glucose monitoring dataset-Applications to the pediatric diabetes population. Pediatr Diabetes. 2017 Nov; 18(7):622-628.
Score: 0.036
-
Forlenza GP, Stewart MW. Diabetic retinopathy in children. Pediatr Endocrinol Rev. 2012 Dec-2013 Jan; 10(2):217-26.
Score: 0.027
-
Nally LM, Sherr JL, Garg SK, Marks BE, Laffel LM, Pihoker C, Accacha SD, Thrasher JR, Abuzzahab MJ, Reed JH, Ekhlaspour L, Belapurkar S, Shulman DI, Sunil B, MacLeish SA, Latif K, Forlenza GP, Castorino K, Lal RA, Bode BW, Broyles FE, Carlson AL, Nwosu BU, Shin J, Ma H, Salbato A, Cordero TL, Treminio Y, McVean JJ, Rhinehart AS, Vigersky RA. Safety and Glycemic Outcomes of the MiniMed 780G System with a Disposable All-in-One Sensor. Diabetes Technol Ther. 2026 Feb; 28(2):109-120.
Score: 0.017
-
Patti ME, Aleppo G, Kruger D, Levy CJ, Bushman J, Umpierrez G, Galindo RJ, Forlenza GP, Carlson AL, McGill JB. The Importance of Expanding Medicare Continuous Glucose Monitoring Coverage for High-Risk Hypoglycemia. Diabetes Technol Ther. 2026 Jun; 28(6):624-631.
Score: 0.017
-
Berget C, Annan SF, Biester T, Choudhary P, Forlenza GP, Peters AL, Renard E, Deiss D. Practical considerations for using the Omnipod® 5 Automated Insulin Delivery System: Clinical experience from the United States and Europe. Diabetes Obes Metab. 2025 Jun; 27(6):2909-2919.
Score: 0.016
-
Biskupiak JE, Ramos M, Levy CJ, Forlenza G, Hopley C, Boyd J, Swift D, Lamotte M, Brixner DI. Cost-effectiveness of the tubeless automated insulin delivery system vs standard of care in the management of type 1 diabetes in the United States. J Manag Care Spec Pharm. 2023 Jul; 29(7):807-817.
Score: 0.014
-
Galindo RJ, Aleppo G, Parkin CG, Baidal DA, Carlson AL, Cengiz E, Forlenza GP, Kruger DF, Levy C, McGill JB, Umpierrez GE. Increase Access, Reduce Disparities: Recommendations for Modifying Medicaid CGM Coverage Eligibility Criteria. J Diabetes Sci Technol. 2024 07; 18(4):974-987.
Score: 0.014
-
Aleppo G, Parkin CG, Carlson AL, Galindo RJ, Kruger DF, Levy CJ, Umpierrez GE, Forlenza GP, McGill JB. Lost in Translation: A Disconnect Between the Science and Medicare Coverage Criteria for Continuous Subcutaneous Insulin Infusion. Diabetes Technol Ther. 2021 10; 23(10):715-725.
Score: 0.012
-
Brown SA, Beck RW, Raghinaru D, Buckingham BA, Laffel LM, Wadwa RP, Kudva YC, Levy CJ, Pinsker JE, Dassau E, Doyle FJ, Ambler-Osborn L, Anderson SM, Church MM, Ekhlaspour L, Forlenza GP, Levister C, Simha V, Breton MD, Kollman C, Lum JW, Kovatchev BP. Glycemic Outcomes of Use of CLC Versus PLGS in Type 1 Diabetes: A Randomized Controlled Trial. Diabetes Care. 2020 08; 43(8):1822-1828.
Score: 0.011
-
Kovatchev B, Anderson SM, Raghinaru D, Kudva YC, Laffel LM, Levy C, Pinsker JE, Wadwa RP, Buckingham B, Doyle FJ, Brown SA, Church MM, Dadlani V, Dassau E, Ekhlaspour L, Forlenza GP, Isganaitis E, Lam DW, Lum J, Beck RW. Randomized Controlled Trial of Mobile Closed-Loop Control. Diabetes Care. 2020 03; 43(3):607-615.
Score: 0.011
-
Cameron FM, Ly TT, Buckingham BA, Maahs DM, Forlenza GP, Levy CJ, Lam D, Clinton P, Messer LH, Westfall E, Levister C, Xie YY, Baysal N, Howsmon D, Patek SD, Bequette BW. Closed-Loop Control Without Meal Announcement in Type 1 Diabetes. Diabetes Technol Ther. 2017 09; 19(9):527-532.
Score: 0.009
-
Huyett LM, Ly TT, Forlenza GP, Reuschel-DiVirgilio S, Messer LH, Wadwa RP, Gondhalekar R, Doyle FJ, Pinsker JE, Maahs DM, Buckingham BA, Dassau E. Outpatient Closed-Loop Control with Unannounced Moderate Exercise in Adolescents Using Zone Model Predictive Control. Diabetes Technol Ther. 2017 06; 19(6):331-339.
Score: 0.009
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|